CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Praxis Precision Medicines Q3 2026 net loss widens 27% to $94.2 million

By Public Technologies
  • Praxis Precision Medicines’ third-quarter 2026 net loss widened 27% year over year to $94.2 million.
  • General and administrative expenses more than tripled year over year to $42.7 million.
  • Cash, cash equivalents and marketable securities totaled $1.3 billion at September 30, 2026, providing an expected runway into 2028.
  • FDA target action dates remain December 27, 2026, for relutrigine and January 29, 2027, for ulixacaltamide.
  • Topline results from relutrigine’s EMERALD study in broad developmental and epileptic encephalopathies are expected in the fourth quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872955) on November 09, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk